Efficacy of Amicar for Children Having Craniofacial Surgery

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine whether Amicar (ε-aminocaproic acid) is effective in reducing blood loss in children undergoing craniofacial reconstruction surgery. The investigators hypothesize that Amicar will decrease intraoperative blood loss and decrease the need for perioperative blood product administration in children undergoing craniofacial surgery.

Clinical Trial Description

Craniosynostosis is a condition in which there is premature fusion of one or more of the sutures between the bones of the skull. Premature fusion of sutures in the skull limits the ability of the cranial vault to expand to accommodate the rapidly growing brain in infancy and early childhood and leads to bony deformation. Left uncorrected, craniosynostosis may adversely impact both neurologic and psychosocial development and in some cases, can result in high intracranial pressure and blindness. Craniofacial (CF) reconstructive surgery is performed in young children with craniosynostosis to improve physical appearance, prevent functional neurologic disturbances, and enhance psychosocial development. Due to the complexities of the surgery as well as the young age and size of the patients, CF reconstruction carries potential life threatening risks and can result in significant morbidity. Reported complications include massive intraoperative hemorrhage, intraoperative cardiac arrest, transfusion-related reactions, venous air embolism, hypotension, coagulopathy, bradycardia, postoperative seizures, surgical site infections, facial swelling with airway compromise, and unplanned postoperative mechanical ventilation. The most severe and most common perioperative issues relate to the rate and extent of blood loss. Fibrinolysis, which impairs adequate hemostasis, has been shown to occur in children during CF reconstruction. This most certainly contributes to the magnitude of blood loss in these types of operations. Thus, targeting this defect in clot hemostasis with the use of antifibrinolytics is a reasonable therapeutic approach. Amicar (ε-aminocaproic acid) is a synthetic lysine analog that blocks the lysine binding sites on plasminogen, resulting in antifibrinolytic activity through inhibition of plasmin formation. We have chosen to study Amicar in this clinical context for a number of reasons. First, major hemorrhage continues to be a significant perioperative issue in this cohort. Secondly, Amicar is commonly and safely administered to children undergoing other types of high-risk surgery (i.e., spinal fusion surgery and open heart surgery). In addition, Amicar is inexpensive and easily administered, making it a viable and novel therapeutic option if shown to be effective for this type of surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02229968
Study type	Interventional
Source	Children's National Research Institute
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 2014
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00769847` - Endoscopic Treatment for Isolated, Single Suture Craniosynostosis	N/A
Completed	`NCT00077831` - Child and Infant Learning Project	N/A
Recruiting	`NCT03231085` - Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child	N/A
Completed	`NCT02287805` - Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their Care	N/A
Enrolling by invitation	`NCT05911139` - Influence of General Anesthesia on the Dynamic Changes in Brain Damage Markers During and After Craniosynostosis Operations in Infancy
Completed	`NCT00912119` - Amicar Pharmacokinetics of Children Having Craniofacial Surgery	Phase 1
Completed	`NCT00106977` - Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)
Withdrawn	`NCT02561728` - Hanger Helmet Study	N/A
Terminated	`NCT00722436` - Tranexamic Acid for Craniofacial Surgery	Phase 4
Completed	`NCT00367796` - Genetic Analysis of Craniosynostosis, Philadelphia Type	N/A
Completed	`NCT01898650` - MRI for Non-invasive Evaluation of Brain Stress	N/A
Active, not recruiting	`NCT03025763` - Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones
Completed	`NCT02188576` - The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery	Phase 4
Completed	`NCT00773643` - Osteogenic Profiling of Tissue From Children With Craniosynostosis	N/A
Enrolling by invitation	`NCT04704284` - Comparing MRI to CT on Pediatric Craniosynostosis.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.